溶血梭菌病即杆菌性血红蛋白尿症(BacillaryHemoglobinuria),又称红尿病(Red Water Disease),是由溶血梭菌(Clostridium haemolyticum)感染牛羊引起的一种在临床上以高热、血红蛋白尿、黄疸和在肝脏出现坏死性梗阻为特征的急性、高度致...溶血梭菌病即杆菌性血红蛋白尿症(BacillaryHemoglobinuria),又称红尿病(Red Water Disease),是由溶血梭菌(Clostridium haemolyticum)感染牛羊引起的一种在临床上以高热、血红蛋白尿、黄疸和在肝脏出现坏死性梗阻为特征的急性、高度致死性毒血症。1926年美国首先报道此病,以后南美洲、欧洲、大洋洲、亚洲的一些国家也陆续发生,大批牛羊死亡,给畜牧业造成严重损失。目前,我国尚未见此病的正式报道。1 病原溶血梭菌曾叫D型诺维氏梭菌(Cl.novyi type D)。展开更多
The aim of this study was to systematically review the evidence on the efficacy and safety of silodosin treatments on lower urinary tract symptoms （LUTS） in men with benign prostatic hyperplasia （BPH） from randomi...The aim of this study was to systematically review the evidence on the efficacy and safety of silodosin treatments on lower urinary tract symptoms （LUTS） in men with benign prostatic hyperplasia （BPH） from randomized controlled trials. We searched PubMed （1966- December 2011）, Embase （1974-December 2011） and the Cochrane Library Database （2011, Issue 12）. The assessed outcome measures were the change from baseline for the International Prostate Symptom Score （IPSS）, quality of life （QoL） score, peak urine maximum flow rate （Qmax）, QoL related to urinary symptoms and adverse effects. Two authors independently assessed the study quality and extracted data. All data were analysed using RevMan 5.1. The meta-analysis included four randomized controlled trials with a total of 2504 patients. The study durations were each 12 weeks. At the follow-up end points, the pooled results showed that the change from baseline for the silodosin group was significantly higher than the placebo group for the IPSS, QoL score and Qmax（mean difference （MD）=-2.78, P〈O.O0001; MD=-O.42, P--O.O04; MD= 1.17, P〈O.OOOOl,respectively） and patients felt more satisfied with QoL related to urinary symptoms in the silodosin group than the placebo group. Ejaculation disorder was the most commonly reported adverse effect. The pooled results also showed that the silodosin group was superior to the 0.2 mg tamsulosin group with respect to the IPSS and QoL score （IPSS： MD=- 1.14, P=O.02; QoL score： MD=-0.26, P=O.02） and inferior to the 0.2 mg tamsulosin group with respect to Qmax （MD=-0.85, P=O.01）. In contrast, there was no significant difference in the incidence of ejaculation disorder and dizziness between the silodosin and 0.2 mg tamsulosin groups. The current meta-analysis suggested that silodosin is an effective therapy for LUTS in men with BPH and is not inferior to 0.2 mg tamsulosin.展开更多
文摘溶血梭菌病即杆菌性血红蛋白尿症(BacillaryHemoglobinuria),又称红尿病(Red Water Disease),是由溶血梭菌(Clostridium haemolyticum)感染牛羊引起的一种在临床上以高热、血红蛋白尿、黄疸和在肝脏出现坏死性梗阻为特征的急性、高度致死性毒血症。1926年美国首先报道此病,以后南美洲、欧洲、大洋洲、亚洲的一些国家也陆续发生,大批牛羊死亡,给畜牧业造成严重损失。目前,我国尚未见此病的正式报道。1 病原溶血梭菌曾叫D型诺维氏梭菌(Cl.novyi type D)。
文摘The aim of this study was to systematically review the evidence on the efficacy and safety of silodosin treatments on lower urinary tract symptoms （LUTS） in men with benign prostatic hyperplasia （BPH） from randomized controlled trials. We searched PubMed （1966- December 2011）, Embase （1974-December 2011） and the Cochrane Library Database （2011, Issue 12）. The assessed outcome measures were the change from baseline for the International Prostate Symptom Score （IPSS）, quality of life （QoL） score, peak urine maximum flow rate （Qmax）, QoL related to urinary symptoms and adverse effects. Two authors independently assessed the study quality and extracted data. All data were analysed using RevMan 5.1. The meta-analysis included four randomized controlled trials with a total of 2504 patients. The study durations were each 12 weeks. At the follow-up end points, the pooled results showed that the change from baseline for the silodosin group was significantly higher than the placebo group for the IPSS, QoL score and Qmax（mean difference （MD）=-2.78, P〈O.O0001; MD=-O.42, P--O.O04; MD= 1.17, P〈O.OOOOl,respectively） and patients felt more satisfied with QoL related to urinary symptoms in the silodosin group than the placebo group. Ejaculation disorder was the most commonly reported adverse effect. The pooled results also showed that the silodosin group was superior to the 0.2 mg tamsulosin group with respect to the IPSS and QoL score （IPSS： MD=- 1.14, P=O.02; QoL score： MD=-0.26, P=O.02） and inferior to the 0.2 mg tamsulosin group with respect to Qmax （MD=-0.85, P=O.01）. In contrast, there was no significant difference in the incidence of ejaculation disorder and dizziness between the silodosin and 0.2 mg tamsulosin groups. The current meta-analysis suggested that silodosin is an effective therapy for LUTS in men with BPH and is not inferior to 0.2 mg tamsulosin.
